Discover innovative startups and track their funding journey
589 ventures found
589 ventures found
Switzerland
No description available
Insilico Medicine is a biotechnology company focused on leveraging generative artificial intelligence (AI) and automation for drug discovery and development. The company aims to accelerate and improve the process of discovering and developing novel therapeutics, with a focus on longevity and sustainability.
Germany
LoopLab is an emerging biotech company developing a first-in-class Fc-Engager platform to induce antigen-specific immune tolerance. Our lead program, LL-HDM, targets house dust mite (HDM) allergy – a major cause of perennial allergic rhinitis and asthma – with a short-course biologic designed to “re-educate” the immune system rather than just suppress symptoms. By fusing disease-specific antigens to an engineered inhibitory Fc domain, our Fc-Engagers selectively silence pathogenic B cells and promote regulatory pathways, aiming for durable remission with minimal systemic immunosuppression. The same modular platform can be rapidly adapted to autoimmune diseases (e.g. celiac disease, bullous pemphigoid) and to prevent anti-drug antibodies against biologics. We are currently in late preclinical development for LL-HDM, supported by €9.6M in seed funding and €1.5M in grants, and preparing a Series A financing of €30–50M in 2026 to reach IND (2027) and First-in-Human (2028). LoopLab is led by a seasoned team with deep experience in immunotherapy, CMC, and clinical development from MSD, Themis, Valneva, Evotec, and others, complemented by an advisory board with strong pharma partnering and clinical trial expertise. Our strategy is to achieve early clinical proof-of-concept in HDM allergy, then monetize via out-licensing and platform partnerships while expanding into high-value autoimmune indications.
Saltsjö Boo, Sweden
Company Overview Utilizer is a MedTech start-up from KTH Royal Institute of Technology, focused on Point-of-Care (POC) diagnostics for bacterial infections. Our mission: - Responsible use of Antibiotics - Save healthcare costs - Improve patient outcomes Solution – First product for market for Urinary Tract Infections, Utilizer®-ID - Miniaturized culture-based diagnostic tool for UTIs at POC - Gold-standard accuracy, results in hours, analyzed via smartphone in 10 seconds - No lab equipment investment - Covers >95% of UTI pathogens - Patent granted in US, pending EU Clinical Validation - Trials at Karolinska: 96% sensitivity, 87% specificity - Usability study at 4 POC sites showing ease of use and fit in current POC workflow with 100% users recommending it for others - IVDR certification in progress Next product in pipeline, Utilizer AST bacterial resistance testing Exit strategy Diagnostic or microbiology company (Roche Diagnostics, Thermo Scientific, Abbott, Biomérieux, Siemens) within 5 years
Boston, United States
ReMinded, Inc. is a MedTech startup on a mission to become the leading solution in salivary diagnostics. Currently, the team is commercializing the first clinical-grade, rapid saliva test that tracks cortisol(a key stress hormone)on demand, unlocking a vital biomarker for psychiatry and behavioral health. The system syncs seamlessly to a desktop platform, enabling clinicians and patients to monitor stress in real-time, reducing reliance on solely subjective assessments for e.g addiction treatment decisions and PTSD.
San Diego, Italy
LipoNexus is commercializing the first and only highly accurate, non-invasive blood test for early detection and diagnosis of Metabolic Associated Steatotic Liver Disease (MASLD). Using a proprietary inflammatory lipid biomarker panel measured by mass spectrometry, the test delivers >95% accuracy and 99% specificity, enabling routine population screening, early intervention, therapy monitoring, and improved outcomes through a widely accessible blood test and reducing reliance on imaging and liver biopsy.
Most women with ovarian cancer experience symptoms, but clinicians still lack a dependable diagnostic tool at that first visit. Existing tests weren’t built to detect early disease and provide limited guidance for symptomatic patients. AOA Dx is closing that gap with AKRIVIS GD™, a first-of-its-kind multi-omic blood test that integrates lipid and protein biomarkers with machine learning to provide a clearer signal for ovarian cancer in symptomatic women. Across multiple datasets, the test has shown strong, consistent performance, including in early-stage disease, and is advancing along a defined FDA pathway. Our goal is to deliver the first practical, accurate diagnostic tool that helps clinicians identify ovarian cancer earlier—addressing a major unmet need with meaningful clinical and market impact.
Germany
sefit develops a clinically guided VR-based digital therapeutic designed to support individuals with autism, ADHD and migraine in managing sensory overload, a core challenge across these conditions. Across Europe, long waiting times of 12–24 months and clinician shortages limit access to structured, real-life exposure therapy. sefit combines immersive real-world VR scenarios, personalised stimulus control and digital biomarkers to enable therapist-guided, measurable exposure training in both clinical and home settings. The system is designed to support daily functioning, social participation and continuity of care. The technology has reached TRL 6 and has been developed and refined in collaboration with over 50 therapists. This submission focuses on de-risking the clinical and regulatory pathway to prepare for scalable deployment across European healthcare systems.
Basel, Switzerland
BRNLIT.AI – A Class-I Ready Digital Therapeutic for Attention and ADHD ADHD affects more than 5 percent of children and adults worldwide, yet access to effective, personalised treatment remains limited. Medication works for many, but not for all, and behavioural therapies are difficult to scale. BRNLIT.AI offers a new pathway: a personalised, non-pharmacological digital therapeutic using an individual’s own brainwave patterns to improve focus and attention regulation. Based on peer-reviewed neuroscience, our technology identifies each user’s unique EEG-derived focus rhythm and delivers a tailored light-stimulation protocol that enhances attentional control within minutes. To protect this breakthrough, we have already filed both EU and US patents covering our personalised neurostimulation method and signal-generation technology. With our upcoming ADHD clinical study, BRNLIT.AI aims to become one of the first digital interventions in Europe to demonstrate measurable, reproducible improvements in attention through personalised neurostimulation. The study will evaluate behavioural outcomes, EEG biomarkers, and symptom reduction across adolescents and adults. Successful validation will enable us to pursue Class I medical device claims, unlocking clinical credibility, reimbursement opportunities, and access to the rapidly growing digital therapeutics market. Our approach combines three strengths rarely found together: a scientifically robust mechanism of action, real-time personalisation powered by AI, and a delivery method that is fully scalable via mobile devices. This positions BRNLIT.AI as a cost-effective, accessible tool for clinicians, parents, and individuals seeking alternatives or complements to existing ADHD treatments. With the ADHD digital therapeutics market projected to exceed USD 2 billion in the coming years, this study is a critical milestone that expands BRNLIT.AI from a high-performance focus tool into a clinically validated neurohealth platform. BRNLIT.AI is not only improving attention; we are redefining how brain-based disorders can be addressed with personalised digital medicine.
Canada
mTatt is a medtech startup developing functional microtattoos for real-time, at-home health monitoring. Using dissolving microneedles — biocompatible structures under 1 mm in length — we painlessly deliver fluorescent sensors into the skin, creating a functional tattoo. These sensors respond to key biomarkers like NT-proBNP, glucose, or electrolytes, providing clinically valuable insights without blood draws or clinical visits. Data is captured via a smartwatch-style wearable and sent to the user’s phone, enabling patients and physicians to track health conditions continuously and intervene early. Our platform makes the diagnostic power of a lab accessible in real time, from the comfort of home.
Long-term organ perfusion as a preclinical platform for drug testing
Nimble Science is transforming gastrointestinal health with the SIMBA™ Capsule — a swallowable, single-use device that safely collects endoscopic-quality fluid samples from the small intestine, an area previously inaccessible without invasive procedures. Combined with our AI-driven data platform, SIMBA delivers precise, multi-optic insights at key physiological timepoints, enabling accurate diagnosis of functional GI disorders like IBS, SIBO, constipation, and diarrhea. We are launching a clinical tool for small intestinal dysbiosis in 2026 and have already established data partnerships across 23 organizations worldwide. Our technology bridges the critical gap between microbiome science and real-world clinical practice, offering clinicians a new diagnostic standard and accelerating therapeutic development for biopharma and nutrition companies.
Germany
SURFACtoBioTech is building the first full‑stack droplet experimentation platform that unites proprietary surfactant chemistry, automated hardware and AI‑enabled analytics into one ecosystem. Our technology converts microliter‑scale samples into 100,000 uniform picoliter droplets from just 10 µL, generating orders of magnitude more high‑quality data at dramatically lower cost and turnaround time. Installed as modular instruments with integrated consumables and software, our platform enables academic, diagnostic and pharma customers to perform high‑throughput assays, structural biology experiments and screening workflows that are currently too slow, expensive or manpower‑intensive. With two patent families covering surfactant chemistry and system integration, >90% blended gross margins and three recurring revenue streams (platform, consumables, software), SURFACtoBioTech is positioned to become the category‑defining infrastructure provider in droplet microfluidics.
SeeQ develops rapid metagenomics-based precision diagnostics for any clinically relevant pathogen from less than 1 mL blood in 6-8 hours. This approach enables faster, more targeted antimicrobial treatment, for better patient outcomes with reduced adverse events and improved quality of life. In turn, health care usage is reduced through shorter hospital stays, lowered readmittance rates and improved antimicrobial stewardship. Our first product, SepSeeQ, has been evaluated into two prospective clinical trials in an acute care setting and chronic infections related to vascular grafts, with additional two studies ongoing in neonatal sepsis and hematological cancers.
We provide a validated pulsatile endovascular aortic training simulator that has already been used in pilot courses both in the angio suite and in dry-lab settings. In a second step, we are developing complementary high-fidelity 3D-printed open vascular models so that the same training center can cover both endovascular and open vascular procedures in a structured 1–2 day course format.
Synagen builds oncology-specific AI agents that automate tumor-board decisions, guideline-based treatment suggestions, and clinical-trial matching, giving every cancer patient access to expert-level care at every visit. We integrate deeply into hospital workflows, reduce documentation and preparation time, and continuously generate structured precision-oncology data that improves outcomes and enables large-scale research over time.
Germany
We convert traditional lateral flow tests into quantitative, lab-grade diagnostic using one drop of blood, enabling both early detection and treatment monitoring. Our proprietary platform combines three core core innovations (1) biosensor test design, (2) AI-driven image analysis and (3) a machine learning-based quantification algorithm. Together, they deliver high-accuracy biomarker measurement in a simple, scalable, self-calibrating and device agnostic format. Our initial focus is ovarian cancer. By integrating multiple biomarkers with patient data such as age, our test outperforms the current CA125 blood test and achieves accuracy comparable to the costly transvaginal-plus-blood testing workflow.
United Kingdom
The MAP-AD is the first and only CE-IVDR-marked prognostic solution designed to predict the progression to Alzheimer’s dementia (AD) in individuals with early memory complaints. The device combines Next-Generation Sequencing of mitochondrial DNA biomarkers with artificial intelligence to analyze disease etiology, cognition, and risk factors. This holistic technology identifies patients who will progress to AD dementia years in advance, even before positive amyloid pathology appears. By shifting healthcare from a late, reactive diagnostic model to an early, precise prognosis, MAP-AD enables clinicians to implement pharmacological therapies or preventive lifestyle interventions before irreversible neurological damage. Uniquely differentiated from the market, MAP-AD offers a distinct value proposition: while diagnostic blood tests (e.g., Lumipulse) detect current amyloid presence, MAP-AD forecasts future cognitive decline. This is critical, as amyloid tests often yield false positives regarding actual dementia progression. MAP-AD prioritizes high sensitivity to ensure at-risk patients are not missed and operates independently of amyloid status. Operationally superior, it analyzes whole blood, eliminating the immediate processing required by plasma-based competitors, reducing indeterminate results, facilitating personalized and precision medicine, and patient stratification.
Italy
Hormo is an integrated, at-home point-of-care (POC) system designed to address the global diagnostic gap in Polycystic Ovary Syndrome (PCOS), a condition affecting 6–13% of women of reproductive age worldwide. By combining a disposable microfluidic biosensor with a portable reader and mobile app, Hormo enables the quantitative, lab-grade detection of three key hormones—LH, Testosterone, and AMH—from a single finger-prick blood drop .This affordable solution empowers women to perform longitudinal monitoring, facilitating early screening and proactive lifestyle management of hormonal imbalances
United States
AI will transform healthcare, but it will not fix the fundamentals: fragmented care, incompatible data, and the absence of trust. Today no one can reliably prove who did what, or whether the work met the standard or created value. Payers carry the risk, providers fight denials, and value-based care cannot scale because multi-party execution cannot be verified. Adino solves this by treating healthcare like an economic system, not a billing system. We provide cryptographic, operational proof that every party completed their part of a care process. This speeds reimbursement, collapses administrative waste, prevents fraud, and makes outcomes traceable. With Adino, payment can be triggered by proof, not trust. We will become the neutral network that moves healthcare value the way Visa moves money, all without ever needing to see the underlying data. We cannot change human nature, so we’re building a system that doesn’t rely on it.
Munich, Germany
BugSense develops a paper-based test for simultaneous infection and resistance detection with a softwarebased readout for point-of-care applications.
Paris, Italy
MSInsight develops advanced AI-driven genomic diagnostics to improve cancer treatment selection and early detection of hereditary cancer syndromes. Our core technology, MSIcare, uses next-generation sequencing and proprietary algorithms to detect microsatellite instability (MSI) with higher precision and consistency than traditional workflows. MSI is a critical tumor-agnostic biomarker used to guide immunotherapy eligibility, prognosis, and therapeutic decisions in colorectal, gastric, endometrial, and other solid tumors. MSI also serves as a key molecular signature for identifying hereditary cancer syndromes driven by mismatch repair deficiency, enabling earlier risk detection and adapted surveillance.
Olomouc, Czech Republic
Kardi Ai is saving lives with AI. We use long-term heart monitoring and artificial intelligence to detect hidden heart rhythm disorders that traditional methods often miss. While standard one-day monitoring detects arrhythmias in roughly 5% of cases, Kardi Ai increases the detection rate to nearly 30% through continuous, long-term monitoring. Our solution gives people an easy way to monitor their heart at home and provides doctors with clear, clinically relevant data — faster diagnosis, better decisions. 300+ lives already saved. Kardi Ai turns prevention into measurable impact.
Kuopio, Finland
Adamant Health is transforming Parkinson's care into patient centric care model. By putting the patients and their caregivers into driver's seat with the help of AI powered treatment optimisation we can create a win-win-win situation where the patient get the help they need on-demand, healthcare system can focus on those requiring their attention and the care costs and resource needs can be brought down to a sustainable level. Optimised care of Parkinson's disease can save up to 2/3rds of the total care costs related to Parkinson's disease according to NHS (NHS RightCare, 2018). By 2050, this means up to 200 billion euros annual savings opportunity globally, while enabling better quality of life for the patients and their families. This is over 20 billion euro annual opportunity that cannot be dismissed.
Page 1 of 25
